BLA
MYGN icon

Balter Liquid Alternatives’s Myriad Genetics MYGN Stock Holding History

Balter Liquid Alternatives’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-4,201
Closed -$139K – 167
2019
Q1 		$139K Buy
+4,201
New +$128K 0.08% 162

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Balter Liquid Alternatives's MYGN Position: Q2 2019 in Review

Balter Liquid Alternatives sold out of Myriad Genetics (MYGN) in Q2 2019, closing a stake of 4,201 shares — an estimated $139K sold.

Balter Liquid Alternatives first reported a position in MYGN in Q1 2019 and held it in 1 quarter. The position peaked at $139K in Q1 2019. 235 funds tracked by Wall St. Rank hold MYGN as of Q2 2019.

  • Balter Liquid Alternatives reported no remaining Myriad Genetics position as of Q2 2019 after selling out during the quarter.
  • Balter Liquid Alternatives sold 4,201 Myriad Genetics shares in Q2 2019, an estimated $139K.
  • Balter Liquid Alternatives first reported a position in Myriad Genetics in Q1 2019 and held it in 1 quarter.
  • Balter Liquid Alternatives's Myriad Genetics position peaked at $139K in Q1 2019.
  • 235 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2019.

Based on Balter Liquid Alternatives's 13F filing for Q2 2019, filed 31 Jul 2019.